Documente Academic
Documente Profesional
Documente Cultură
Characteristic
Cediranib
(20 mg)
(n 502)
Placebo
(n 358)
No. % No. %
Age, years
Median 58.0 59.0
Range 2-83 22-82
Sex
Male 299 59.6 212 59.2
Female 203 40.4 146 40.8
Race/ethnicity
White 320 63.7 254 70.9
Black 7 1.4 5 1.4
Asian 166 33.1 88 24.6
Other 9 1.8 11 3.1
WHO performance status
0 288 57.4 209 58.4
1 214 42.6 149 41.6
Type of cancer
Colon 288 57.4 232 64.8
Rectal 214 42.6 126 35.2
Baseline liver covariate
ALP 320 U/L and albumin 3.5 g/dL 397 79.1 274 76.5
Other combinations of ALP and albumin 105 20.9 84 23.5
Initial diagnosis to random assignment, months
6 326 64.9 245 68.4
6 to 12 22 4.4 12 3.4
12 to 24 57 11.4 37 10.3
24 to 36 48 9.6 28 7.8
36 49 9.8 36 10.1
Prior therapies
Radiotherapy 69 13.7 40 11.2
Adjuvant chemotherapy 104 20.7 80 22.3
Abbreviation: ALP, alkaline phosphatase.